People: Meridian Bioscience Inc (VIVO.O)
VIVO.O on Nasdaq
21.70USD
1:49pm EDT
21.70USD
1:49pm EDT
Price Change (% chg)
$-0.15 (-0.69%)
$-0.15 (-0.69%)
Prev Close
$22.01
$22.01
Open
$21.88
$21.88
Day's High
$21.96
$21.96
Day's Low
$21.61
$21.61
Volume
41,870
41,870
Avg. Vol
172,936
172,936
52-wk High
$23.05
$23.05
52-wk Low
$16.19
$16.19
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
William Motto |
71 | 2008 | Executive Chairman of the Board |
John Kraeutler |
64 | 2008 | President, Chief Executive Officer, Director |
Melissa Lueke |
49 | 2009 | Chief Financial Officer, Executive Vice President, Secretary |
Marco Calzavara |
58 | 2011 | President and Managing Director of Meridian Bioscience Europe |
Lawrence Baldini |
53 | 2005 | Executive Vice President - Operations and Information Systems |
Richard Eberly |
51 | 2012 | Executive Vice President; President of Meridian Life Science |
Vecheslav Elagin |
45 | 2011 | Senior Vice President - Research and Development |
Susan Rolih |
63 | 2008 | Senior Vice President - Regulatory Affairs and Quality Assurance |
Marviette Johnson |
44 | Vice President - Human Resources | |
James Anderson |
70 | 2009 | Independent Director |
David Phillips |
74 | 2000 | Independent Director |
Robert Ready |
72 | 1986 | Independent Director |
Biographies
| Name | Description |
|---|---|
William Motto |
Mr. William J. Motto is Executive Chairman of the Board of Meridian Bioscience Inc., since January 2008. Mr. Motto has more than 45 years of experience in the pharmaceutical and diagnostics products industries, is a founder of Meridian and has been Chairman of the Board since 1977. Mr. Motto became Executive Chairman of the Board in January 2008. Before forming Meridian, Mr. Motto served in various capacities for Wampole Laboratories, Inc., Marion Laboratories, Inc. and Analytab Products, Inc., a division of American Home Products Corp. Mr. Motto’s experience as Meridian’s founder, his breadth of experience within the pharmaceutical and diagnostics products industries, and his entrepreneurial approach to assessing Meridian’s growth opportunities, give him unparalleled insights into all aspects of Meridian’s business and operations, which he, in turn, is able to contribute to the Board as its Executive Chairman. |
John Kraeutler |
Mr. John A. Kraeutler is President, Chief Executive Officer, Director of Meridian Bioscience Inc. Mr. Kraeutler has more than 40 years of experience in the medical diagnostics industry and joined Meridian as Executive Vice President and Chief Operating Officer in January 1992. In July 1992, Mr. Kraeutler was named President of Meridian, and in January 2008, Mr. Kraeutler was named Chief Executive Officer of Meridian. Before joining Meridian, Mr. Kraeutler served as Vice President, General Manager for a division of Carter-Wallace, Inc. Prior to that, he held key marketing and technical positions with Becton, Dickinson and Company and Organon, Inc. Mr. Kraeutler’s long-time service to Meridian, all in an executive capacity, has given him insight into, and familiarity with, all aspects of Meridian’s business and the strategic vision for its continued success, and makes his service on the Board extremely beneficial. |
Melissa Lueke |
Ms. Melissa A. Lueke is Chief Financial Officer, Executive Vice President, Secretary of Meridian Bioscience Inc., since November 2009. Ms. Lueke was appointed Vice President, Chief Financial Officer and Secretary in January 2001 and Executive Vice President, Chief Financial Officer and Secretary in November 2009. Prior to her appointment, Ms. Lueke served as Meridian’s Controller since March 2000 and Acting Secretary from July 20, 2000 to January 23, 2001. Before joining Meridian, Ms. Lueke was employed by Arthur Andersen LLP from June 1985 to January 1999, most recently as a Senior Audit Manager. |
Marco Calzavara |
Mr. Marco G. Calzavara is President and Managing Director of Meridian Bioscience Europe of Meridian Bioscience Inc. He founder of the Bioline Group, which Meridian acquired July 20, 2010, was appointed President and Managing Director of Meridian Bioscience Europe in April 2011. Prior to this appointment, Mr. Calzavara had served as President of the Bioline Group of Companies since 1992. |
Lawrence Baldini |
Mr. Lawrence J. Baldini is Executive Vice President - Operations and Information Systems of Meridian Bioscience Inc., since October 2005. He was appointed Vice President of Operations in April 2001 and Executive Vice President, Operations and Information Systems in October 2005. Before joining Meridian, Mr. Baldini held various operations management positions with Instrumentation Laboratories and Fisher Scientific. |
Richard Eberly |
Mr. Richard L. Eberly is Executive Vice President of Meridian Bioscience Inc and President of Meridian Life Science. He was appointed Vice President of Sales and Marketing in January 1997, Executive Vice President in May 2000, Executive Vice President, General Manager of Meridian Life Science in February 2003, Executive Vice President and President Meridian Life Science in October 2005 and Chief Commercial Officer in February 2011. In October 2012, he was re-appointed President of Meridian Life Science, and no longer serves as Chief Commercial Officer. He has over 20 years of experience in the medical diagnostics industry and joined Meridian in March 1995. Prior to his appointment to Vice President of Sales and Marketing, Mr. Eberly served as the Director of Sales for Meridian. Before joining Meridian, he held key sales and marketing positions at Abbott Diagnostics, Division of Abbott Laboratories. |
Vecheslav Elagin |
Dr. Vecheslav A. Elagin, Ph.D., is Senior Vice President - Research and Development of Meridian Bioscience Inc. He joined Meridian in August 2009 as Vice President of Research and Development, was appointed Senior Vice President of Research and Development in November 2011, and promoted to Executive Vice President of Research and Development in June 2012. Before joining Meridian, Dr. Elagin held various executive research and development positions, most recently with Madison Life Science (August 2008 – August 2009), EraGen Biosciences (May 2006 – August 2008) and Third Wave Technologies (June 2003 – May 2006). |
Susan Rolih |
Ms. Susan A. Rolih is Senior Vice President - Regulatory Affairs and Quality Assurance of Meridian Bioscience Inc., since April 2008. She was appointed Vice President of Regulatory Affairs and Quality Assurance in May 2001 and Senior Vice President of Regulatory Affairs and Quality Assurance in April 2008. Before joining Meridian, Ms. Rolih held various regulatory and quality positions with Immucor, Inc. |
Marviette Johnson |
Ms. Marviette D. Johnson is Vice President - Human Resources of Meridian Bioscience Inc. She served as Director of Human Resources from January 2006 to April 2008, as Senior Director of Human Resources from April 2008 to November 2009 and was appointed to her current position of Vice President of Human Resources in November 2009. Before joining Meridian in 2003, Ms. Johnson held various human resources leadership positions within the hospitality industry, including with Marriott International and Millennium Copthorne. |
James Anderson |
Mr. James M. Anderson is Independent Director of Meridian Bioscience, Inc. Mr. Anderson serves as Chairman of the Nominating and Corporate Governance Committee. He currently serves as Advisor to the President of Cincinnati Children’s Hospital Medical Center (“CCHMC”), following his retiring as President and Chief Executive Officer of CCHMC on December 31, 2009. He has also served on the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland, retiring in 2012. Prior to joining the staff of CCHMC, Mr. Anderson was a partner in the general corporate law department at Taft, Stettinius & Hollister for 24 years (1968-1977; 1982-1996) and president of U.S. operations at Xomox Corporation, a publicly-traded manufacturer of specialty process controls (1977-1982). Mr. Anderson has also served as director of Gateway Investment Advisors (1997-2008). |
David Phillips |
Mr. David C. Phillips is Independent Director of Meridian Bioscience, Inc. Mr. Phillips serves as Chairman of the Audit Committee. Mr. Phillips spent 32 years with Arthur Andersen LLP. His service with this firm included several managing partner leadership positions. After retiring from Arthur Andersen in 1994, Mr. Phillips became Chief Executive Officer of Downtown Cincinnati, Inc., which is responsible for economic revitalization of Downtown Cincinnati. Mr. Phillips retired from DCI in 1999 to devote full time to Cincinnati Works, Inc., an organization dedicated to reducing the number of people living below the poverty level by assisting them to strive towards self-sufficiency through work, and his financial consulting services. Mr. Phillips has also served as a director of Cintas Corporation, retiring in 2012, and as a director of Summit Mutual Funds, a registered investment company, through 2009. |
Robert Ready |
Mr. Robert J. Ready is Independent Director of Meridian Bioscience, Inc. Mr. Ready serves as Chairman of the Compensation Committee. Mr. Ready founded LSI Industries Inc., Cincinnati, Ohio in 1976, which engineers, manufactures and markets commercial/industrial lighting and graphics products, and is currently its Chief Executive Officer and Chairman of its Board of Directors. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
William Motto |
844,534 |
John Kraeutler |
809,201 |
Melissa Lueke |
421,197 |
Marco Calzavara |
580,828 |
Lawrence Baldini |
399,080 |
Richard Eberly |
537,308 |
Vecheslav Elagin |
661,465 |
Susan Rolih |
-- |
Marviette Johnson |
-- |
James Anderson |
-- |
David Phillips |
-- |
Robert Ready |
-- |
As Of 29 Sep 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
William Motto |
152,363 | 2,704,583 |
John Kraeutler |
417,466 | 7,166,770 |
Melissa Lueke |
82,875 | 1,414,659 |
Marco Calzavara |
0 | 0 |
Lawrence Baldini |
58,750 | 981,150 |
Richard Eberly |
65,500 | 1,065,167 |
Vecheslav Elagin |
0 | 0 |
Susan Rolih |
0 | 0 |
Marviette Johnson |
0 | 0 |
James Anderson |
0 | 0 |
David Phillips |
0 | 0 |
Robert Ready |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
KRAEUTLER JOHN A |
5,000 | $19.63 |
READY ROBERT J |
5,000 | $21.69 |
MOTTO WILLIAM J |
2,500 | $21.59 |
MOTTO TODD W |
1,016,331 | $0.00 |
LUEKE MELISSA A |
15,750 | $19.83 |
LUEKE MELISSA A |
5,250 | $0.00 |
LUEKE MELISSA A |
15,750 | $0.00 |
LUEKE MELISSA A |
5,250 | $19.88 |
MOTTO WILLIAM J |
683,417 | $0.00 |
EBERLY RICHARD L |
15,750 | $0.00 |
EBERLY RICHARD L |
5,250 | $0.00 |
EBERLY RICHARD L |
31,500 | $20.47 |
EBERLY RICHARD L |
10,500 | $0.00 |
MOTTO WILLIAM J |
1,500 | $20.50 |
READY ROBERT J |
6,000 | $20.29 |
MOTTO WILLIAM J |
15,750 | $20.34 |
MOTTO WILLIAM J |
15,750 | $0.00 |
BALDINI LAWRENCE J |
32,500 | $20.07 |
BALDINI LAWRENCE J |
32,500 | $20.00 |
ROLIH SUSAN A |
22,500 | $2.80 |
READY ROBERT J |
1,800 | $19.46 |
LUEKE MELISSA A |
7,500 | $0.00 |
KRAEUTLER JOHN A |
10,000 | $0.00 |
ROLIH SUSAN A |
7,500 | $0.00 |
JOHNSON MARVIETTE D |
7,500 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
